Report
EUR 12.98 For Business Accounts Only

TAIKO PHARMACEUTICAL sees an upgrade to Neutral thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to TAIKO PHARMACEUTICAL (JP), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as moderately risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Neutral; the title, however, remains unattractive. As of the analysis date November 30, 2021, the closing price was JPY 808.00 and its target price was estimated at JPY 686.90.
Underlying
Taiko Pharmaceutical Co. Ltd.

Taiko Pharmaceutical is a pharmaceutical company which operates in three business segments. The Pharmaceutical Product segment is engaged in the manufacture, sale and export of non-prescription ("OTC") gastrointestinal drugs under the names of "SEIROGAN," "SEIROGAN TOI-A (sugar coated tablet)" and "PISHUT." The Infection Control segment is involved in the planning, development and sale of infection control products under the names of "CLEVERIN," "WE'LL SHIELD" and "LISPASS," which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacture and sale of bath additives, soap and pyroligneous acid for horticultural use.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch